Can Thymidine Phosphorylase Be a Predictive Marker for Gemcitabine and Doxifluridine Combination Chemotherapy in Cholangiocarcinoma?: Case Series
Unresectable cholangiocarcinoma is poorly responded to chemotherapy, especially for the case refractory to gemcitabine and cisplatin. Here, we tested whether high expression of thymidine phosphorylase (TP) can be a predictive biomarker for the indicator for gemcitabine and doxifluridine combination...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Wolters Kluwer Health
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603134/ |